Tag Archive for: mcrpc
Personalized Treatment for Advanced Prostate Cancer: The Power of Multi-Tracer PET Imaging
/in Preclinical Research/by MaxPhase 2 trial: Delaying Systemic Treatment in Metastatic Prostate Cancer – A New Approach
/in Clinical Trial, Metastatic, Phase 2/by MaxPromising Results for 177Lu-PSMA-I&T in Prostate Cancer Treatment
/in Clinical Trial, Metastatic, Phase 3/by MaxBenfo-Oxythiamine Shows Promise as a Radiosensitizer in mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxPositive Phase 1 Data Supports Phase 2 of 177Lu rhPSMA-10.1 for mCRPC
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxDarolutamide Plus ADT: A Great Treatment Option for Metastatic Hormone-Sensitive Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy
Latest Posts
- Healthy Eating After Prostate Cancer Tied to Lower Risk of Frailty March 24, 2026
- Higher Vitamin D Levels Before Diagnosis Linked to Better Prostate Cancer Survival March 24, 2026
- Newsletter 12/2026 March 22, 2026
- JMKX007129: A Next‑Generation AR‑NTD Inhibitor for Overcoming Resistance in mCRPC March 20, 2026